The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).
Description: Number of patients with EGF-R gene mutation
Measure: EGF-R gene mutation in nationwide cohort Time: 1 YearDescription: Number of patients with K-RAS gene mutation
Measure: K-RAS gene mutation in nationwide cohort Time: 1 yearDescription: Number of patients with EML4-ALK translocation
Measure: EML4-ALK translocation in nationwide cohort Time: 1 yearDescription: Number of patients with BRAF gene mutation
Measure: BRAF gene mutation in nationwide cohort Time: 1 yearDescription: Number of patients with HER2 gene mutation
Measure: HER2 gene mutation in nationwide cohort Time: 1 yearDescription: Number of patients with PI3K gene mutation
Measure: PI3K gene mutation in nationwide cohort Time: 1 yearCohort
There is one SNP
Regarding stage IV non-squamous NSCLC patients, 7 biomarkers are assessed including activating EGFR mutations, EML4-ALK translocation and EGFR T790M, KRAS, BRAF, HER2 and PI3KCA mutations. --- T790M ---